



Rec'd PGT/PTO 25 NOV 2005

ATTORNEY DOCKET NO. 21101.0021U2
APPLICATION NO. 10/516,662
SHEET 1 OF 4

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete If Known	
	Application Number	10/516,662
	Filing Date	June 2, 2003
	First Named Inventor	Bock et al.
	Group Art Unit	Unassigned 1656
	Examiner Name	Unassigned CARLSON

U.S. PATENT DOCUMENTS							
Examiner's Initials	Cite No.	Document No.	Date	Name	Class	Subclasses	Filing Date (if appropriate)
rep	A1	6,878,813	04/12/05	Bock et al.	530	393	12/11/01
	A2	5,204,253	04/20/93	Sanford et al.	435	459	
	A3	5,420,252	05/30/95	Kato et al.	530	393	
	A4	5,618,713	04/08/97	Zettlemeissl et al.	435	226	
	A5	5,700,663	12/23/97	Zettlemeissl et al.	435	69.6	
fcc	A6	5,843,705	12/01/98	DiTullio et al.	800	7	

FOREIGN PATENT DOCUMENTS					
Examiner's Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Translation Yes/No
fcc	A7	EP 0 568 833 A1	08/04/93	Kato et al.	
	A8	WO 90/09737	07/09/90	Blood Research Center	
	A9	WO 91/00291	01/10/91	Akzo	
fcc	A10	WO 95/05853	03/02/95	Carson et al.	

NON-PATENT DOCUMENTS		
Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)
kcc	A11	Backovic and Gettins, "Insight into residues critical for antithrombin function from an expanded database of sequences that includes frog, turtle and ostrich antithrombins." J. Proteome Res. 2002 1:367-373.
	A12	Bayston et al. "Familial overexpression of beta antithrombin caused by an Asn135Thr substitution." Blood 1999 93:4242-7.
	A13	Bick et al. "Antithrombin III patterns in disseminated intravascular coagulation." Am. J. Clin. Pathol. 1980 73(4):577-83.
	A14	Blauhut et al. "Substitution of antithrombin III in shock and DIC: a randomized study." Thromb. Res. 1985 39(1):81-9.
	A15	Bock et al., "Cleaved and inactivated antithrombin III in bronchoalveolar lavage (BAL) samples from acute respiratory distress (ARDS) and at-risk for ARDS patents," Proteases/Antiproteases, seminar, Amer. J. Respir. Crit. Care Med., 2001, A63. (Poster Abstract)
	A16	Bock et al. "Cloning and expression of the cDNA for human antithrombin III." Nucleic Acids Res. 1982 10(24):8113-25.
	A17	Brennan et al. "Physiological variant of antithrombin-III lacks carbohydrate sidechain at Asn 135." FEBS Lett. 1987 219(2):431-6.
	A18	Buller and Cate, "Acquired antithrombin III deficiency: laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate." Am. J. Med. 1989 87(3B):44S-48S.
	A19	Carlson et al. "Comparison of the behavior in vivo of two molecular forms of antithrombin III." Biochem. J. 1985 225:557-64.
	A20	Carrell and Owen, "Plakalbumin, alpha 1-antitrypsin, antithrombin and the mechanism of inflammatory thrombosis." Nature. 1985 317(6039):730-2.
	A21	Cohen et al. "In vivo inactivation of antithrombin III is promoted by heparin during cardiopulmonary bypass." J. Invest. Surg. 1992 5:45-9.
kcc	A22	Cunningham et al. "Development of an elastase-resistant antithrombin through mutagenesis at P4." Blood. 1995 86(10 Supp.):375A. (Abstract)

Examiner Signature: <i>K Carlson</i>	Date Considered: <i>11-7-07</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Rec'd PCT/PTO 25 NOV 2005

ATTORNEY DOCKET NO. 21101.0021U2

APPLICATION NO. 10/516,662

SHEET 2 OF 4

INFORMATION DISCLOSURE STATEMENT LIST		Complete if Known	
		Application Number	10/516,662
		Filing Date	June 2, 2003
		First Named Inventor	Bock <i>et al.</i>
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
(Use as many sheets as necessary)			
KCC	A23	Cunningham et al. "Impact of mutations at the P4 and P5 position on the reation of antithrombin with thrombin and elastase." Thromb. Res. 1997 88(2):171-81.	
	A24	Damus and Wallace, "Immunologic measurement of antithrombin III-heparin cofactor and alpha2 macroglobulin in disseminated intravascular coagulation and hepatic failure coagulopathy." Thromb Res. 1975 6(1):27-38.	
	A25	deAgostini et al. "Localization of anticoagulant active heparan sulfate proteoglycans in vascular endothelium: Antithrombin binding on cultured endothelial cells and perfused rat aorta." J. Cell Biol. 1990 111:1293-1304.	
	A26	Delsharnmar et al. "Abnormal proteolysis (DIC)--successful treatment with antithrombin III concentrate and a concentrate containing F XIII and native von Willebrand factor." J. Intern. Med. 1989 225(1):21-7.	
	A27	Dickneite and Paques, "Reduction of mortality with antithrombin III in septicemic rats: a study of Klebsiella pneumoniae induced sepsis." Thromb Haemost. 1993 69(2):98-102.	
	A28	Dunzendorfer et al. "Cell-surface heparan sulfate proteoglycanmediatedregulation of human neutrophil migration by the serpin antithrombin III." Blood 2001 97:1079-85.	
	A29	Emerson et al. "Efficacy of antithrombin III supplemtation in animal models of fulminant Eschericia coli endotoxemia or bacteremia." Am. J. Med. 1989 87:27S-33S.	
	A30	Emerson et al. "Protection against disseminated intravascular coagulation and death by antithrombin-III in the Escherichia coli endotoxemic rat." Circ Shock. 1987 21(1):1-13.	
	A31	Ersdal-Badju et al. "Elimination of glycosylation heterogeneity affecting heparin affinity of recombinant human antithrombin III by expression of a beta-like variant in baculovirusinfected insect cells." Biochem. J. 1995 310:323-30.	
	A32	Fourrier et al. "Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation." Chest. 1993 104(3):882-8.	
	A33	Franzen et al. "Structural studies on the carbohydrate portion of human antithrombin III." J. Biol. Chem. 1980 255(11):5090-3.	
	A34	Frebelius et al. "Thrombin inhibition by antithrombin III on the subendothelium is explained by the isoform AT-beta." Thromb. Vasc. Biol. 1996 16:1292-7.	
	A35	Hedin et al. "Antithrombin III inhibits thrombin-induced proliferation in human arterial smooth muscle cells." Arterioscler Thromb. 1994 14(2):254-60.	
	A36	Hellgren et al. "Antithrombin III concentrate as adjuvant in DIC treatment. A pilot study in 9 severely ill patients." Thromb Res. 1984 35(4):459-66.	
	A37	Hellgren et al. "Blood coagulation and fibrinolytic factors and their inhibitors in critically ill patients." Intensive Care Med. 1984 10(1):23-8.	
	A38	Hoffmann et al. "Antithrombin effects on endotoxin-induced microcirculatory disorders are mediated mainly by its interaction with microvascular endothelium." Crit. Care Med. 2002 30:218-25.	
	A39	Ishiguro, K. et al. "Complete antithrombin deficiency in mice results in embryonic lethality." J. Clin. Invest. 2000 106(7):873-878.	
	A40	Jairajpuri et al. "Elimination of P1 arginine-393 interaction with underlying glutamic acid-255 partially activates antithrombin III for thrombin inhibition but not factor Xa inhibition." J. Biol. Chem. 2002 277:24460-5.	
	A41	Jochum et al. "Effect of human granulocytic elastase on isolated human antithrombin III." Hoppe Seylers Z Physiol Chem. 1981 362(2):103-12.	
A42	Jochum, "Influence of high-dose antithrombin concentrate therapy on the release of cellular proteinases, cytokines, and soluble adhesion molecules in acute inflammation." Semin Hematol. 1995 32(4 Suppl 2):19-32.		
KCC	A43	Jordan et al. "Heparin promotes the inactivation of antithrombin by neutrophil elastase." Science. 1987 237(4816):777-9.	
Examiner Signature: KCCarbow		Date Considered: 11-7-07	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

25 NOV 2005

ATTORNEY DOCKET NO. 21101.0021U2
APPLICATION NO. 10/516,662
SHEET 3 OF 4

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/516,662
		Filing Date	June 2, 2003
		First Named Inventor	Bock <i>et al.</i>
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
rec	A44	Jordan, "Antithrombin in vertebrate species: conservation of the heparin-dependent anticoagulant mechanism." Arch. Biochem. Biophys. 1983 227(2):587-95.	
	A45	Kato et al. "Recombinant antithrombin III mutations with enhanced antithrombin activity without heparin." 69 th Scientific Sessions, Abstract 4336, 1996 94:8 Supp., p. I-741. (Abstract)	
	A46	Kocsis et al. "Heparin-coated stents." J. Long-Term Effects of Medical Implants. 2000 10:19-45.	
	A47	Kurachi et al. "Inhibition of bovine factor IXa and factor Xbeta by antithrombin III." Biochemistry. 1976 15(2):373-7.	
	A48	Lammle et al. "Plasma prekallikrein, factor XII, antithrombin III, C1(-)-inhibitor and alpha 2-macroglobulin in critically ill patients with suspected disseminated intravascular coagulation (DIC)." Am. J. Clin. Pathol. 1984 82(4):396-404.	
	A49	Lawson et al. "Complex-dependent inhibition of factor VIIa by antithrombin III and heparin." J. Biol. Chem. 1993 268(2):767-70.	
	A50	Mammen et al. "Human antithrombin concentrates and experimental disseminated intravascular coagulation." Semin. Thromb. Hemost. 1985 11(4):373-83.	
	A51	Mant et al. "Haemorrhagic complications of heparin therapy." Lancet. 1977 1(8022):1133-5.	
	A52	Marcum et al. "Microvascular heparin-like species with anticoagulant activity." Am. J. Physiol. 1983 245(5 Pt 1):H725-33.	
	A53	Minnema et al. "Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli." Blood. 2000 95(4):1117-23.	
	A54	Mizuochi et al. "Structural studies of the carbohydrate moiety of human antithrombin III." Arch. Biochem. Biophys. 1980 203(1):458-65.	
	A55	Nakajima et al., "Mapping the extended substrate binding site of cathepsin G and human leukocyte elastase," J. Biol. Chem. 1979 254:4027.	
	A56	Nuijens et al. "Plasma elastase alpha 1-antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators in fatal sepsis." J. Lab. Clin. Med. 1992 119(2):159-68.	
	A57	O'Reilly et al. "Antiangiogenic activity of the cleaved conformation of the serpin antithrombin." Science. 1999 285(5435):1926-8.	
	A58	Oelschläger et al. "Antithrombin III inhibits nuclear factor kappa B activation in human monocytes and vascular endothelial cells." Blood 2002 99:4015-20.	
	A59	Olson et al. "Identification of critical molecular interactions mediating heparin activation of antithrombin. Implications for the design of improved heparin anticoagulants." Trends Cardiovasc. Med. 2002 12:198-205.	
	A60	Olson et al. "Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement." J. Biol. Chem. 1992 267(18):12528-38.	
	A61	Ostrovsky et al. "Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion." Circulation. 1997 96(7):2302-10.	
	A62	Owen et al. "P1 variant antithrombins Glasgow (393 Arg to His) and Pescara (393 Arg to Pro) have increased heparin affinity and are resistant to catalytic cleavage by elastase. Implications for the heparin activation mechanism." FEBS Lett. 1991 280(2):216-20.	
	A63	Petersen et al., Primary structure of antithrombin III (heparin cofactor) - partial homology between α 1-antitrypsin and antithrombin-III." The Physiological Inhibitors of Coagulation and Fibrinolysis, Elsevier/North Holland Biomedical Press. 1979 pp. 43-54.	
rec	A64	Peterson and Blackburn, "Isolation and characterization of an antithrombin III variant with reduced carbohydrate content and enhanced heparin binding." J. Biol. Chem. 1985 260(1):610-5.	

Examiner Signature: <i>K C Carlson</i>	Date Considered: <i>11-7-07</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Rec'd PCT/PTO 25 NOV 2005

ATTORNEY DOCKET NO. 21101.0021U2
APPLICATION NO. 10/516,662
SHEET 4 OF 4

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/516,662
		Filing Date	June 2, 2003
		First Named Inventor	Bock <i>et al.</i>
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
rcc	A65	Picard and Bock, "Rapid and efficient one-tube PCR-based mutagenesis method." <i>Methods in Mol. Biol.</i> Vol. 67, PCR Cloning Protocols. From molecular cloning to genetic engineering. B.A. White Humana Press, Totowa, NJ, 1996, 183-8.	
	A66	Picard <i>et al.</i> "A rapid and efficient one-tube PCR-based mutagenesis technique using Pfu DNA polymerase." <i>Nucleic Acid Res.</i> 1994 22(13):2587-91.	
	A67	Picard <i>et al.</i> "Partial glycosylation of antithrombin III asparagine-135 is caused by the serine in the third position of its N-glycosylation consensus sequence and is responsible for production of the beta-antithrombin III isoform with enhanced heparin affinity." <i>Biochemistry.</i> 1995 34(26):8433-40.	
	A68	Rao <i>et al.</i> "Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa." <i>Blood.</i> 1993 81(10):2600-7.	
	A69	Rosenberg and Damus, "The purification and mechanism of action of human antithrombin-heparin cofactor." <i>J. Biol. Chem.</i> 1973 248(18):6490-505.	
	A70	Rosenberg, "Chemistry of the hemostatic mechanism and its relationship to the action of heparin." <i>Fed. Proc.</i> 1977 36(1):10-8.	
	A71	Rothenburger <i>et al.</i> "Treatment of thrombus formation associated with the MicroMed DeBakey VAD using recombinant tissue plasminogen activator." <i>Circulation</i> 2002 106(suppl 1): I-189-92.	
	A72	Ruf and Mueller, "Tissue factor in cancer angiogenesis and metastasis." <i>Curr. Opin. Hematol.</i> 1996 3(5):379-84.	
	A73	Seitz <i>et al.</i> "Participation and interactions of neutrophil elastase in haemostatic disorders of patients with severe infections." <i>Eur. J. Haematol.</i> 1987 38(3):231-40.	
	A74	Stephens <i>et al.</i> "Site directed mutagenesis of the reactive center (serine 394) of antithrombin III." <i>J. Biol. Chem.</i> 1988 263(31):15849-52.	
	A75	Tani <i>et al.</i> "Thrombin enhances lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis." <i>Am. J. Respir. Cell Mol. Biol.</i> 1991 5(1):34-40.	
	A76	Tejada, M.L. and Deeley, R.G. "Cloning of an avian antithrombin: developmental and hormonal regulation of expression." <i>Thromb. Haemost.</i> 1995 73(4):654-661.	
	A77	Turk <i>et al.</i> "The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change." <i>Biochemistry.</i> 1997 36(22):6682-91.	
	A78	Uchiba <i>et al.</i> "Antithrombin III (AT III) prevents LPS-induced pulmonary vascular injury: novel biological activity of AT III." <i>Semin. Thromb. Hemost.</i> 1997 23(6):583-90.	
	A79	van Boven and Lane, "Antithrombin and its inherited deficiency states." <i>Semin. Hematol.</i> 1997 34(3):188-204.	
	A80	Varga <i>et al.</i> "Infectious entry pathway of adenovirus type 2." <i>J. Virol.</i> 1991 65(11):6061-70.	
	A81	Vinazzer, "Antithrombin III in shock and disseminated intravascular coagulation." <i>Clin. Appl. Thrombosis/Hemostasis.</i> 1995 1:62-5.	
	A82	Warren <i>et al.</i> "High-dose antithrombin III in severe sepsis: a randomized controlled trial." <i>JAMA.</i> 2001 286(15):1869-78.	
	A83	Witmer and Hatton, "Antithrombin III-beta associates more readily than antithrombin III-alpha with uninjured and de-endothelialized aortic wall in vitro and in vivo." <i>Arteriosclerosis and Thrombosis.</i> 1991 11:530-9.	
A84	Wolff <i>et al.</i> "Direct gene transfer into mouse muscle in vivo." <i>Science.</i> 1990 247(4949 Pt 1):1465-8.		
rcc	A85	Zendeherouh, Ph.D. Dissertation, "Novel proteinase inhibitors for use in treatment of sepsis." Temple Univ. School of Medicine, publically available at the Univeristy of Michigan dissertation archive in 1999.	

Examiner Signature: <i>MCCarson</i>	Date Considered: <i>11-7-07</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

#2

ATTORNEY DOCKET NO. 21101.0021U2
APPLICATION NO. 10/516,662
SHEET 1 OF 1

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/516,662
Filing Date	3/13/2006
First Named Inventor	Bock et al.
Group Art Unit	1656
Examiner Name	Carlson, Karen C.

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

NON-PATENT DOCUMENTS

[illegible]

Examiner Signature:

Signature: B. C. Carlsen

Date Considered:

11-7-07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.